Table 3.
Changes in management due to additional findings on PET/MRI
| Patient no. | Cancer type | Staging/restaging | Additional findings on PET/MRI | Management change relative to PET/CT |
|---|---|---|---|---|
| 15 | NET | Staging | Metastases in left liver lobe not visible on [68Ga]Ga-DOTANOC-PET/CT | Liver surgery in addition to primary tumor surgery |
| 22 | NSCLC | Staging | More brain metastases than on [18F]FDG-PET/CT | No additional MRI of the brain needed for radiation therapy planning |
| 27 | Pancreatic adenocarcinoma | Staging | Metastases in both liver lobes not visible on [18F]FDG-PET/CT | Palliative chemotherapy only instead of primary tumor surgery and chemotherapy |
| 63 | Melanoma | Staging | Brain metastases not visible on [18F]FDG-PET/CT | Additional radiation therapy/no additional MRI of the brain needed |
| 82 | Melanoma | Staging | Brain metastases not visible on [18F]FDG-PET/CT | Additional radiation therapy / no additional MRI of the brain needed |
| 88 | Cervical cancer | Staging | No urinary bladder infiltration by primary tumor ([18F]FDG-PET/CT suggestive of bladder infiltration) | Surgery and chemotherapy instead of just chemotherapy |
| 93 | NET | Restaging | Metastasis in left liver lobe not visible on [68Ga]Ga-DOTANOC-PET/CT | Follow-up MRI examinations at 3–6-month intervals |
| 100 | Colorectal adenocarcinoma | Restaging | More metastases in both liver lobes than visible on [18F]FDG-PET/CT | Chemotherapy only vs. chemotherapy and liver surgery |
| 106 | Pancreatic adenocarcinoma | Staging | Metastases in right liver lobe not visible on [18F]FDG-PET/CT | Palliative chemotherapy only vs. primary tumor surgery and chemotherapy |
| 110 | Melanoma | Staging | More brain metastases than on [18F]FDG-PET/CT | No additional MRI of the brain needed for radiation therapy planning |
| 115 | Pancreatic adenocarcinoma | Staging | Metastases in both liver lobes not visible on [18F]FDG-PET/CT | Palliative chemotherapy only vs. primary tumor surgery and chemotherapy |
| 119 | NET | Restaging | Metastases in right liver lobe not visible on [68Ga]Ga-DOTANOC-PET/CT | Liver surgery |
| 127 | Melanoma | Staging | More metastases in left liver lobe than visible on [18F]FDG-PET/CT | No liver surgery due to multiple metastases |
| 139 | NSCLC | Staging | Brain metastasis not visible on [18F]FDG-PET/CT | Additional radiation therapy/no additional MRI of the brain needed |
| 139 | NSCLC | Restaging | New brain metastasis not visible on [18F]FDG-PET/CT | No additional MRI of the brain needed for radiation therapy planning |
| 140 | NSCLC | Staging | Brain metastasis not visible on [18F]FDG-PET/CT | Additional radiation therapy/no additional MRI of the brain needed |
| 151 | NSCLC | Restaging | Brain metastasis not visible on [18F]FDG-PET/CT | Additional radiation therapy/no additional MRI of the brain needed |
| 160 | NSCLC | Staging | Brain metastasis not visible on [18F]FDG-PET/CT | Additional radiation therapy/no additional MRI of the brain needed |
| 160 | NSCLC | Restaging | New brain metastases not visible on [18F]FDG-PET/CT | No additional MRI of the brain needed for radiation therapy planning |
| 212 | Melanoma | Restaging | Multiple metastases in both liver lobes instead of single metastasis in right liver lobe, as suggested by [18F]FDG-PET/CT | Therapy switch from ipilimumab to pembrolizumab due to progression instead of stable disease |
| 256 | NSCLC | Restaging | Brain metastasis not visible on [18F]FDG-PET/CT | Additional radiation therapy/no additional MRI of the brain needed |
| 260 | NSCLC | Staging | Brain metastasis not visible on [18F]FDG-PET/CT | Additional radiation therapy/no additional MRI of the brain needed |
| 263 | NSCLC | Staging | Equivocal adrenal gland lesion on [18F]FDG-PET/CT, diagnosed as fat-containing adenoma on chemical shift MRI | No additional MRI required to complete staging |